Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522858 | PMC |
| http://dx.doi.org/10.4244/EIJ-E-24-00053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The future of sirolimus-coated balloon use in percutaneous coronary intervention.
EuroIntervention
November 2024
Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Contemporary Use of Drug-Coated Balloons for Coronary Angioplasty: A Comprehensive Review.
J Clin Med
October 2024
Division of Cardiology, Catheterization Laboratory, Montevergine Clinic, 83013 Mercogliano, Italy.
The interventional treatment of coronary artery disease (CAD) has undergone significant improvements thanks to technological innovations. Nowadays, percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation is the standard of care for the treatment of CAD. Nevertheless, the non-negligible incidence of in-stent restenosis (ISR) and suboptimal results in various anatomical settings has led to the development of drug-coated balloons (DCBs).
View Article and Find Full Text PDFMagic Touch sirolimus-coated balloon: animal and clinical evidence of a coronary sirolimus drug-coated balloon.
Future Cardiol
October 2024
DCB Academy, Milano, Italy.
The Magic Touch sirolimus-coated balloon (SCB) was recently introduced in Europe and features robust clinical technology different from other devices on the market. This device is able to deliver a sufficient sirolimus dose to the target segment to reduce neointimal proliferation with very little exposure downstream and no apparent adverse effects at sustained high drug concentrations. The SCB represents a promising novelty within the drug-coated balloon arena due to its mid-term efficacy and safety in the treatment of coronary artery disease, especially in and small-vessel coronary lesions.
View Article and Find Full Text PDFPushing the Boundaries: Drug-Coated Balloons to Treat a Calcified and Thrombotic Lesion in Acute Coronary Syndrome.
Am J Case Rep
October 2022
Cardiology Division, Heart Center, Luzerner Kantonsspital, Luzern, Switzerland.
BACKGROUND Use of drug-coated balloons (DCB) is an important research topic. Many companies are quickly developing new, cutting-edge technologies and means to deliver drugs. Moreover, interest is growing in use of sirolimus-coated balloons, a promising technology in the "leaving nothing behind" era.
View Article and Find Full Text PDF[Use of drug-coated balloons for interventions on bifurcation lesions of coronary arteries].
Angiol Sosud Khir
September 2021
Department of Endovascular Diagnosis and Treatment, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.
Interventions on bifurcation lesions of the coronary bed are one of the most complicated tasks of interventional cardiology. Recent trends are toward active study of using drug-eluting balloons for interventions in this type of lesions. Using such technique makes it possible to minimize the risks associated with implantation of stents in sites of coronary artery bifurcations with good angiographic results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!